Across TCGA pan-cancer cohorts, MIRLET7G RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of MIRLET7G’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where MIRLET7G RNA is repressed in tumor relative to normal tissue. In most cancer types MIRLET7G is over-expressed in tumor, although a few such as BRCA and LUSC show the opposite, repressed pattern.

BRCA, STAD, and LUSC are the cancer types where MIRLET7G tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MIRLET7G RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	All	III,IV	−0.491	<.001	4	view →
STAD	Male	III,IV	+0.411	.027	2	view →
LUSC	Female	All	−0.337	.025	2	view →
KIRC	Male	II,III,IV	+0.055	.040	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: MIRLET7G RNA expression & survival · all MIRLET7G data types